EUVIMEDEUVIMED entdecken
Crossref

Immune Checkpoint Inhibitors (ICI) in the Functional Cure of Hepatitis B: A Narrative Review

I Komang Wisuda Dwija Putra, I Ketut Mariadi, Gde Somayana

The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy · 30.04.2026 · 27 (1) · 60-69

DOI: 10.24871/271202660-69 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, online erschienen am 30.04.2026. Verfasst von I Komang Wisuda Dwija Putra und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic hepatitis B (CHB) remains a major global health burden, largely due to the persistence of covalently closed circular DNA (cccDNA) within infected hepatocytes, which hinders complete viral eradication despite long-term antiviral therapy. In recent years, immune checkpoint inhibitors (ICIs) have emerged as a potential therapeutic strategy by restoring exhausted antiviral immune responses. This review explores the mechanisms of action of ICIs, their current application in hepatitis B virus (HBV) infection, and their potential role in achieving a functional cure. Available evidence indicates that ICIs targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) are capable of partially restoring HBV-specific T-cell function and reducing intrahepatic cccDNA transcriptional activity. Early-phase clinical studies have demonstrated encouraging outcomes, including declines in hepatitis B surface antigen (HBsAg) levels and occasional HBsAg loss; however, consistent achievement of a functional cure remains limited. Notably, combination strategies involving ICIs with therapeutic vaccines or nucleos(t) ide analogues appear to enhance antiviral efficacy compared with monotherapy. In conclusion, ICIs represent a promising adjunctive approach for CHB treatment and may contribute to the pursuit of a functional cure. Nevertheless, further well-designed clinical trials are required to establish their long-term safety, optimal treatment combinations, and effectiveness, particularly in HBV-endemic populations.

Zitieren

APA

Putra, I. K. W. D., Mariadi, I. K., & Somayana, G. (2026). Immune Checkpoint Inhibitors (ICI) in the Functional Cure of Hepatitis B: A Narrative Review. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 27(1), 60-69. https://doi.org/10.24871/271202660-69

Vancouver

Putra IKWD, Mariadi IK, Somayana G. Immune Checkpoint Inhibitors (ICI) in the Functional Cure of Hepatitis B: A Narrative Review. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy. 2026;27(1):60-69. doi:10.24871/271202660-69

BibTeX
@article{Putra2026,
  author = {Putra, I Komang Wisuda Dwija and Mariadi, I Ketut and Somayana, Gde},
  title = {Immune Checkpoint Inhibitors (ICI) in the Functional Cure of Hepatitis B: A Narrative Review},
  journal = {The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy},
  year = {2026},
  volume = {27},
  number = {1},
  pages = {60--69},
  doi = {10.24871/271202660-69}
}
Kostenlos starten →